BioSpace News Archive

Ology Bioservices Inc., a biologics contract development and manufacturing organization (CDMO), announced today that the Department of Defense (DOD), through the Joint Science and Technology Office of the Defense Threat Reduction Agency (DTRA), has awarded the company with three biomanufacturing contracts with a combined value of more than $16 million.

QC-validated cell lines optimized to work alongside Horizon’s Edit-R predesigned sgRNA products and DharmaFECT transfection reagents

Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the overall health of NASH patients, announced today the pricing of an underwritten public offering of 5,228,166 shares of its common stock at a public offering price of $36.00 per share,

89bio, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, announced the pricing of an upsized underwritten public offering of 2,649,600 shares of its common stock at a public offering price of $27.50 per share.

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the first patient has been dosed in its Phase 1 trial evaluating CA-4948,

MYOS RENS Technology Inc. (“MYOS” or “the Company”) (NASDAQ: MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announced today, the publication of a study that evaluated the impact of Fortetropin on the rate of muscle protein synthesis in older adults.

International medical imaging IT and cybersecurity company Sectra will install its enterprise imaging solution in many of CHRISTUS Health’s U.S. locations.

Halberd Corp. (OTC PINK:HALB) today explains the second of three (3) COVID -19 (Coronavirus) patent pending treatments - “Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients” - which was filed with the U.S. Patent and Trademark Office on April 8, 2020.

New location provides pharmacy services and home delivery to its growing base of hospice patients in the Greater Philadelphia area and Northeastern US.

The University of Colorado Anschutz Medical Campus and ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that the paper entitled “Dynamic Regulation of SARS-CoV-2 Binding and Cell Entry Mechanisms in Remodeled Human Ventricular Myocardium” (Bristow MR, et al. https://doi.org/10.1016/j.jacbts.2020.06.007 was published in JACC: Basic to Translational Science (JBTS),